A distinct clinical entity of uveitis associated with human T lymphotropic virus type 1
HTLV-I uveitis and a significant correlation was found between Graves' disease and HTLV-I uveitis. Sixteen ofthe 93 patients with HTLV-I uveitis (17.2%) had a previous history of Graves' disease. Fifteen patients were female (15/60, 25-0%) and one was male (1/33, 3.0%). Interestingly, uveitis occurred after the onset of Graves' disease in all cases. On the other hand, none of 222 patients with idiopathic uveitis who were seronegative to HTLV-I had a history of Graves' disease. Although the mechanisms by which HTLV-I causes the correlation between uveitis and Graves' disease are unknown, the present data suggest that immune mediated or autoimmune mechanisms are involved in HTLV-I uveitis. (BrJ Ophthalmol 1994; 78: 163-166) Human T lymphotropic virus type 1 (HTLV-I) is a human retrovirus highly endemic in the Caribbean islands, parts of central Africa, and south west Japan (Miyazaki, Kagoshima, and Okinawa).' The virus is a causative agent for T cell malignancy such as adult T cell leukaemia/ lymphoma (ATL),23 and chronic myelopathy such as HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP). 45 Recently, we have reported seroepidemiological, clinical, and virological studies carried out in an HTLV-I endemic area in Japan which suggest that HTLV-I is also a causative agent for uveitis previously diagnosed as idiopathic:
(1) HTLV-I infection was a high risk factor for idiopathic uveitis67; (2) (Fig 1) . The patient was treated with systemic prednisolone (30 mg/day) for 1 week, after which treatment was slowly tapered. The vitreous opacities decreased in 4 weeks on prednisolone treatment and the visual acuity of his left eye was 1 2 on 1 October 1991. The diagnostic laboratory examinations for uveitis were normal except for the serum antibodies to HTLV-I which were positive by ELISA and x256 by PA. The examinations of thyroid function at the time of uveitis onset disclosed hyperthyroidism as shown in Table 2 .
Discussion
The present study reported for the first time a close relation between Graves' disease and uveitis in HTLV-I carriers. In a series of 93 patients with HTLV-I uveitis, 16 patients (17 2%) had a previous history of Graves' disease and all 16 developed uveitis after the onset of Graves' disease. The time interval from the onset of Graves' disease to uveitis varied from 7 months to 12 years. As a result of the treatment for Graves' disease, nine patients had normal thyroid function at the time of uveitis and two patients (cases 12 and 16) had hypothyroid function, though four patients (cases 3, 4, 9 and 11) still had hyperthyroid function. Although the mechanisms by which HTLV-I causes the high correlation between uveitis and Graves' disease are unknown, three hypotheses could be considered. Firstly, an excess of thyroid hormone may modify the immune response or activate the virus replication and/or expand the number of HTLV-I infected lymphocytes. Then these circulating and/or locally infiltrating HTLV-I infected cells may affect the intraocular tissues, leading to uveitis. The second hypothesis concerns the effects of the medication used to treat Graves' disease (methimazole). The changes in thyroid hormone from high level to normal or low level caused by the medication or the agent itself could be related to the development of uveitis. The third hypothesis is that there might be a correlation between HTLV-I infection and Graves' disease similar to the high association between HTLV-I infection and uveitis.
As for the first hypothesis, it does not seem to reconcile with the fact that many of the patients were euthyroid or even hypothyroid at the time of uveitis, although the hypothesis could explain the order ofthe onset ofthe two diseases -that is, from Graves' disease to uveitis in all 16 patients. The second hypothesis is most unlikely because no significant incidence of uveitis has been reported in patients with Graves' disease on antithyroid drugs. As for the third hypothesis, we carried out a seroepidemiological survey in a large number of patients with Graves' disease to determine if there is any significant association between HTLV-I infection and Graves' disease."I The seroprevalence of HTLV-I in patients with Graves' disease was 78/1177 (6 6%) (male; 14/260 (5 4%), female 64/917 (7 0%)) and this was significantly higher than that of control, 44/852 (5 1%)" (p<0 05, by logistic model'2). This result indicates that there is a significant association between HTLV-I infection and Graves' disease. However, it is still unknown why Graves' disease occurred bqfore the onset of uveitis in the 16 patients. It can be hypothesised that the eye is more resistant to the changes caused by HTLV-I infection than is the thyroid, because the eye is isolated and protected from the systemic circulation by the blood-ocular barrier.
The high association between Graves' disease and idiopathic uveitis in HTLV-I carriers suggests that HTLV-I infection produces changes in the immune system which predispose to autoimmune disease, since both Graves' disease and idiopathic uveitis are considered to be immune mediated or autoimmune diseases. It is well known that HTLV-I is transmitted to CD4 positive T lymphocytes and the HTLV-I infected T lymphocytes express interleukin 2 receptors and produce a variety of lymphokines, indicating that HTLV-I infected lymphocytes are activated T lymphocytes.'3 It is well documented that the activated lymphocytes play a significant role in the development of uveitis. '4 There are several case reports suggesting an association of human retroviruses and autoimmune diseases: Sjogren's syndrome,' multiple sclerosis, '6 
